Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05227287 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ADH1 and ADH2 Disease Monitoring Study (DMS)

Study acronym: CLARIFY
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv17
  2. Study sites: 29 to 27v16
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 100 to confirmed 95
    • Study sites: 31 to 29
    v15
  4. Enrollment target: 60 to 100v14 Show 5 more changesShow less
    • Primary endpoints: 7 to 8
    • Study sites: 26 to 31
    • Eligibility criteria expanded, about 38 words
    • Secondary endpoints expanded, about 83 words
    • Study title shortened, about 1 word
  5. Study sites: 24 to 26v13
Show 11 earlier versionsHide 11 earlier versions
  1. Study sites: 22 to 24v12
  2. Study sites: 21 to 22v11
  3. Primary endpoints: 9 to 7
    • Study completion date: Nov 2028 to Dec 2028
    • Eligibility criteria expanded, about 12 words
    v10
  4. Study sites: 15 to 21v9
  5. Re-verified, no change to tracked fieldsv8
  6. Study sites: 7 to 15v7
  7. Study sites: 4 to 7v6
  8. Study sites: 3 to 4v5
  9. Study sites: 2 to 3v4
  10. 2 versions Re-verified since Feb 7, 2022, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospective (over time into the future) data collection.
Trial Details
NCT Number NCT05227287
Lead Sponsor Calcilytix Therapeutics, Inc., a BridgeBio company
Conditions
(from sponsor)		 Autosomal Dominant Hypocalcemia
Related terms Calcium Metabolism Disorders, Hypercalciuria, Hypercalciuric Hypocalcemia, Familial, Hypocalcemia, Hypoparathyroidism, Metabolic Diseases, Muscular Diseases, Musculoskeletal Abnormalities, Musculoskeletal Diseases, Nephrocalcinosis, Nephrolithiasis
Enrollment 95 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov